FOXP3 and graft versus host disease: Apart from its ability to depress the pro-inflammatory environment of GvHD, Ruxolitinib shapes T cell mediated immune response toward a FoxP3+ regulatory T cell (Treg) polarization mostly by a sparing mechanism of the JAK3-STAT5 pathway [18].